RAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L–mutated, anti-EGFR–refractory metastatic colorectal cancer in Gaucher’s disease
Abstract RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and cl...